Evidence map›Paper›PMID 40358770›Full record

ArticleMikrochimica acta2025

Bright nanoparticle-labeled lateral flow immunoassay for rapid quantitative detection of tacrolimus in human plasma.

Lun Bian, Yu Fu, Zihao Xu, Biru Wu, Junyu Liang, Wei Guo, Guanfeng Lin, Fang Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lun Bian *Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Yu Fu *Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Zihao XuBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Biru WuBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Junyu LiangDepartment of Clinical Laboratory, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
Wei GuoGuangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Guanfeng LinKey Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China. lingf@smu.edu.cn.
Fang HuBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. hufang19@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus (Tac), a macrolide immunosuppressant widely employed in organ transplantation, requires therapeutic drug monitoring owing to the narrow treatment window. In this study, we established an innovative ultrabright nanoparticle-based lateral flow immunoassay (LFIA) for one-step rapid quantitative detection of Tac in human plasma. The aggregation-induced emission (AIE) luminogen, AIE490, was embedded in polystyrene nanoparticles to assemble the ultrabright AIE490NP as a highly sensitive fluorescence marker. Carboxyl-modified Tac was used to couple with carrier proteins to synthesize complete antigens coated on the test line. Under optimized conditions, the limit of detection for Tac is 0.589 ng/mL in human plasma. The linear range was 1-1000 ng/mL, completely covering the safe plasma concentration of Tac, 5-15 ng/mL. The intra- and inter-assay precisions of the established method are below 17.99% and 19.94%, respectively. In addition, for measuring the plasma concentration of Tac in 139 clinical samples, the results of the LFIA are consistent with those of LC-MS/MS (R

Indexed as

Immunosuppressive AgentsNanoparticlesTacrolimusFluorescent DyesHumansImmunoassayLimit of DetectionPolystyrenesReproducibility of ResultsFluorescent DyesImmunosuppressive AgentsPolystyrenesTacrolimusAggregation-induced emissionFluorescence detectionLateral flow immunoassayTacrolimus

Identifiers

PMID40358770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.